Analysis outlines how R&D competition influences market structure and social welfare, suggesting privatization may not always be beneficial.
This study examines endogenous choices of competition strategies in a vertically related mixed market in which an integrated public firm and a downstream firm, subject to forward passive ownership (FPO) by an input supplier, may engage in R&D investment. We demonstrate that Bertrand (price‐quantity) competition emerges when both levels of FPO and product substitutability are low (high), which proves detrimental (beneficial) to society. Compared to the case where R&D decisions are not involved, we find that the possibility that the socially desirable equilibrium (i.e., price‐quantity competition) appears becomes larger under R&D competition. Finally, when the FPO level is low but the product substitutability is high, welfare enhancement attributed to the privatization of a public firm can be more constrained under R&D investment. Our findings suggest that antitrust agencies should monitor not only the FPO level but also R&D‐engaged firms' coordination on the competition mode, while it is socially beneficial to encourage R&D investment when the FPO level is high, rather than privatizing the integrated public firm.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: